Class 2 drug alert, action within 48 hours, patient level recall esmya 5mg tablets (ulipristal acetate)

Following the PRAC recommendation, Esmya is being recalled, and the market authorisation suspended whilst a safety review is being conducted following reports of liver failure requiring liver transplant. Patients supplied Esmya are to be contacted to ask them to stop taking it.

Source:

Medicines and Healthcare products Regulatory Agency